Cargando…
The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study
In the present study, we aimed to investigate the survival benefit from definitive local treatment (LT) for hepatocellular carcinoma patients with distant metastasis (mHCC). We retrospectively analyzed mHCC patients from Surveillance, Epidemiology, and End Results (SEER) Database. The patients’ clin...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882428/ https://www.ncbi.nlm.nih.gov/pubmed/29517658 http://dx.doi.org/10.1097/MD.0000000000010020 |
_version_ | 1783311467719688192 |
---|---|
author | Su, Mingxue Zhao, Yuanyuan Liu, Jianjun |
author_facet | Su, Mingxue Zhao, Yuanyuan Liu, Jianjun |
author_sort | Su, Mingxue |
collection | PubMed |
description | In the present study, we aimed to investigate the survival benefit from definitive local treatment (LT) for hepatocellular carcinoma patients with distant metastasis (mHCC). We retrospectively analyzed mHCC patients from Surveillance, Epidemiology, and End Results (SEER) Database. The patients’ clinical and pathological characteristics were analyzed. Overall survival (OS) was calculated by Kaplan-Meier method. Independent risk factors associated with disease special mortality (DSM) were identified by multivariable regression analysis. A total of 7187 mHCC patients from SEER database were identified. A total of 258 (3.6%) patients had received surgery treatment (ST), 64 (0.9%) patients underwent radiotherapy (RT), and 6865 (95.5%) patients were identified to no surgery or radiation therapy group (NSR). Compared with the patients in NSR group, patients who received ST (hazard ratio [HR]: 0.26, 95% confidence interval [CI] 0.22–0.31, P < .001) and RT (HR: 0.51, 95% CI 0.38–0.67, P < .001) had decreased DSM. Patients with age >50 years, female, and T3 or higher stage were associated with increased DSM. The present study demonstrated the survival benefit of definitive LT in mHCC patients. However, a large randomized clinical trial to validate the role of LT in mHCC is necessary in the future. |
format | Online Article Text |
id | pubmed-5882428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-58824282018-04-11 The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study Su, Mingxue Zhao, Yuanyuan Liu, Jianjun Medicine (Baltimore) 5700 In the present study, we aimed to investigate the survival benefit from definitive local treatment (LT) for hepatocellular carcinoma patients with distant metastasis (mHCC). We retrospectively analyzed mHCC patients from Surveillance, Epidemiology, and End Results (SEER) Database. The patients’ clinical and pathological characteristics were analyzed. Overall survival (OS) was calculated by Kaplan-Meier method. Independent risk factors associated with disease special mortality (DSM) were identified by multivariable regression analysis. A total of 7187 mHCC patients from SEER database were identified. A total of 258 (3.6%) patients had received surgery treatment (ST), 64 (0.9%) patients underwent radiotherapy (RT), and 6865 (95.5%) patients were identified to no surgery or radiation therapy group (NSR). Compared with the patients in NSR group, patients who received ST (hazard ratio [HR]: 0.26, 95% confidence interval [CI] 0.22–0.31, P < .001) and RT (HR: 0.51, 95% CI 0.38–0.67, P < .001) had decreased DSM. Patients with age >50 years, female, and T3 or higher stage were associated with increased DSM. The present study demonstrated the survival benefit of definitive LT in mHCC patients. However, a large randomized clinical trial to validate the role of LT in mHCC is necessary in the future. Wolters Kluwer Health 2018-03-09 /pmc/articles/PMC5882428/ /pubmed/29517658 http://dx.doi.org/10.1097/MD.0000000000010020 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0 |
spellingShingle | 5700 Su, Mingxue Zhao, Yuanyuan Liu, Jianjun The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study |
title | The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study |
title_full | The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study |
title_fullStr | The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study |
title_full_unstemmed | The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study |
title_short | The role of definitive local treatment in metastatic hepatocellular carcinoma patients: A SEER-based study |
title_sort | role of definitive local treatment in metastatic hepatocellular carcinoma patients: a seer-based study |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882428/ https://www.ncbi.nlm.nih.gov/pubmed/29517658 http://dx.doi.org/10.1097/MD.0000000000010020 |
work_keys_str_mv | AT sumingxue theroleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy AT zhaoyuanyuan theroleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy AT liujianjun theroleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy AT sumingxue roleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy AT zhaoyuanyuan roleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy AT liujianjun roleofdefinitivelocaltreatmentinmetastatichepatocellularcarcinomapatientsaseerbasedstudy |